Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study [PDF]
, 2008 A. Moretti, G. De Mattia, O. Laurenti
core +1 more source
Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024. [PDF]
Pharmacy (Basel)Alsaif M, Blumer Z.
europepmc +1 more source
Lower Risk of Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients Diagnosed with Type 2 Diabetes for >10 years: Meta-Analysis of 5 Randomized Trials [PDF]
, 2013 Jiten Vora +4 more
openalex +1 more source
Comparable glycemic outcomes with insulin glargine and insulin degludec during exercise in adolescents with type 1 diabetes using a standardized management protocol. [PDF]
Diabetes Obes MetabRabbone I +10 more
europepmc +1 more source
NPH Insulin Versus Insulin Glargine Versus NPH Insulin Plus Insulin Glargine for the Treatment of Dexamethasone-Induced Hyperglycemia in Patients With COVID-19: A Retrospective Cohort Study. [PDF]
J Pharm Technol, 2023 Fornwald CR, Tuttle NS, Murphy JA.
europepmc +1 more source
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (
, 2015 Yasuo Terauchi +6 more
openalex +1 more source
Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study [PDF]
Robert Ritzel +7 more
openalex +1 more source
Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia [PDF]
, 2018 Nebojša Lalić +4 more
openalex +1 more source
A disproportionality analysis of insulin glargine in the overall population and in pregnant women using the FDA adverse event reporting system (FAERS) database. [PDF]
PLoS OneLiu S +6 more
europepmc +1 more source